A5091041425- Monoclonal and Polyclonal Antibodies Research
- Drug Transport and Resistance Mechanisms
- Hemophilia Treatment and Research
- HIV/AIDS drug development and treatment
- Platelet Disorders and Treatments
- vaccines and immunoinformatics approaches
- Biosimilars and Bioanalytical Methods
- RNA and protein synthesis mechanisms
- Cancer-related gene regulation
- Blood Coagulation and Thrombosis Mechanisms
- Pharmacological Effects and Toxicity Studies
- CAR-T cell therapy research
- Complement system in diseases
- Advanced biosensing and bioanalysis techniques
- Transgenic Plants and Applications
- Trace Elements in Health
- Protein purification and stability
- CRISPR and Genetic Engineering
- Pediatric Hepatobiliary Diseases and Treatments
- Adenosine and Purinergic Signaling
- SARS-CoV-2 and COVID-19 Research
- MicroRNA in disease regulation
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
Center for Biologics Evaluation and Research
2016-2025
United States Food and Drug Administration
2015-2025
Food and Drug Administration
2024-2025
Fats and Proteins Research Foundation
2024
Children's Hospital of Los Angeles
2023
Biogen (United States)
2013
National Center for Biotechnology Information
2012
Garvan Institute of Medical Research
2012
National Cancer Institute
2000-2008
National Institutes of Health
2000-2008
Synonymous single-nucleotide polymorphisms (SNPs) do not produce altered coding sequences, and therefore they are expected to change the function of protein in which occur. We report that a synonymous SNP Multidrug Resistance 1 ( MDR 1) gene, part haplotype previously linked gene product P-glycoprotein (P-gp), nonetheless results P-gp with drug inhibitor interactions. Similar mRNA levels, but conformations, were found for wild-type polymorphic P-gp. hypothesize presence rare codon, marked by...
<ns4:p>Therapeutic protein drugs are an important class of medicines serving patients most in need novel therapies. Recently approved recombinant therapeutics have been developed to treat a wide variety clinical indications, including cancers, autoimmunity/inflammation, exposure infectious agents, and genetic disorders. The latest advances protein-engineering technologies allowed drug developers manufacturers fine-tune exploit desirable functional characteristics proteins interest while...
The repurposing of the CRISPR/Cas microbial adaptive immune system for gene editing has resulted in an exponential rise new technologies and promising approaches treating numerous human diseases. While some being currently developed involve ex vivo by CRISPR/Cas9, many more potential applications will require editing. use this technology comes with challenges, one which is response to Cas9, a protein origin. Thus, prevalence pre-existing antibodies Cas9 could also be relevant parameter....
P-glycoprotein (Pgp) is an ATP-dependent hydrophobic natural product anticancer drug efflux pump whose overexpression confers multidrug resistance to tumor cells. The work reported here deals with the elucidation of energy requirement for substrate interaction Pgp during catalytic cycle. We show that K d (412 nM) analogue [ 125 I]iodoarylazidoprazoin not altered by presence nonhydrolyzable nucleotide 5′-adenylylimididiphosphate and vanadate ( = 403 nM). Though binding per se does affect...
Abstract ATP-binding cassette (ABC) proteins include the best known mediators of resistance to anticancer drugs. In particular, ABCB1 [MDR1/P-glycoprotein (P-gp)] extrudes many types drugs from cancer cells, thereby conferring those agents. Attempts overcome P-gp-mediated drug using specific inhibitors P-gp has had limited success and faced therapeutic challenges. As an alternative approach inhibitors, we characterize a thiosemicarbazone derivative (NSC73306) identified in generic screen as...
High-Throughput (HT) SELEX combines (Systematic Evolution of Ligands by EXponential Enrichment), a method for aptamer discovery, with massively parallel sequencing technologies.This emerging technology provides data global analysis the selection process and simultaneous discovery large number candidates but currently lacks dedicated computational approaches their analysis.To close this gap, we developed novel insilico methods to analyze HT-SELEX uti- lized them study emergence polymerase...
P-glycoprotein (Pgp) is a plasma membrane protein whose overexpression confers multidrug resistance to tumor cells by extruding amphipathic natural product cytotoxic drugs using the energy of ATP. An elucidation catalytic cycle Pgp would help design rational strategies combat and further our understanding mechanism ATP-binding cassette transporters. We have recently reported (Sauna, Z. E., Ambudkar, S. V. (2000) <i>Proc. Natl. Acad. Sci. U. A.</i> 97, 2515–2520) that there are two...
Abstract Motivation: Systematic Evolution of Ligands by EXponential Enrichment (SELEX) represents a state-of-the-art technology to isolate single-stranded (ribo)nucleic acid fragments, named aptamers, which bind molecule (or molecules) interest via specific structural regions induced their sequence-dependent fold. This powerful method has applications in designing protein inhibitors, molecular detection systems, therapeutic drugs and antibody replacement among others. However, full...
<h3>Background</h3> Haemophilia B is caused by genetic aberrations in the <i>F9</i> gene. The majority of these are non-synonymous mutations that alter primary structure blood coagulation factor IX (FIX). However, a synonymous mutation c.459G>A (Val107Val) was clinically reported to result mild haemophilia (FIX coagulant activity 15%–20% normal). mRNA patients showed no skipping or retention introns and/or change levels, suggesting integrity does not contribute origin disease affected...
Abstract Synonymous codons occur with different frequencies in organisms, a phenomenon termed codon usage bias. Codon optimization, common term for variety of approaches used widely by the biopharmaceutical industry, involves synonymous substitutions to increase protein expression. It had long been presumed that variants, which, definition, do not alter primary amino acid sequence, have no effect on structure and function. However, critical mass reports suggests variations may impact...